Biora Therapeutics (BIOR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BIOR Biora Therapeutics

Watchlist

0.6677
+0.0127+1.94%

Close Jul 26 16:00 ET

0.6897
+0.0220+3.29%

Post 20:02 ET

24.00MMarket Cap-104P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
BenzingaJul 22 06:41 ET
Biora Therapeutics Analyst Ratings
BenzingaJul 22 06:40 ET · Ratings
Biora Therapeutics Buy Rating Confirmed by Positive Phase 1 Trial Outcomes and NaviCap Technology Potential
TipRanksJul 22 06:15 ET · Ratings
Biora Therapeutics Advances Ulcerative Colitis Treatment With BT-600 Trial Success
TipRanksJul 18 08:29 ET
Express News | Biora Therapeutics Announces Supplemental Data From Phase 1 Clinical Trial of BT-600 as Presented at Kol Event
ReutersJul 18 08:00 ET
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results From Phase 1 Clinical Trial of BT-600 on July 17, 2024
GlobeNewswireJul 8 08:00 ET

Comments

Jaguar8

Jul 18 07:03

NEWS

$Biora Therapeutics(BIOR.US)$
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...

joeyboulevard

Jul 15 12:24

$Biora Therapeutics (BIOR.US)$ anyone know why sudden rise?

Jaguar8

Jul 8 07:04

NEWS

$Biora Therapeutics(BIOR.US)$
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...